枸橼酸托法替布的结构确证
收稿日期: 2026-04-20
修回日期: 2026-09-01
录用日期: 2026-09-08
网络出版日期: 2026-09-08
基金资助
泰山产业领军人才资助项目(tscx202507102); 山东省重点研发计划资助项目(2022CXPT046)
Structural Elucidation of Tofacitinib Citrate
1. Lunan Pharmaceutical Group Co., Ltd., Linyi 276005, China; 2. National Engineering and Technology Research Center of Chirality Pharmaceutical, Linyi 273400, China; 3. School of Chemistry and Chemical Engineering, Taishan University, Tai’an 271021, China.
Received date: 2026-04-20
Revised date: 2026-09-01
Accepted date: 2026-09-08
Online published: 2026-09-08
Supported by
Taishan Industry Leading Talent Program(tscx202507102); the Key R&D Program of Shandong Province(2022CXPT046)
杨宇 , 郭立红 , 余军厚 , 张敏敏 , 张明明 , 翟立海 . 枸橼酸托法替布的结构确证[J]. 波谱学杂志, 0 : 0 . DOI: 10.11938/cjmr2026-3217
Tofacitinib citrate is a kinase inhibitor that alleviates symptoms such as joint swelling, pain, and deformity by modulating signal transduction in the immune system and it has been applied in the treatment of rheumatoid arthritis. In this study, the structure of tofacitinib citrate was analyzed by ultraviolet absorption spectroscopy, infrared absorption spectroscopy, mass spectrometry, nuclear magnetic resonance spectroscopy (1H NMR, 13C NMR, DEPT, 1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC and 1D-TOCSY) and single crystal diffraction. The 1H and 13C NMR signals of tofacitinib citrate were assigned. In addition, the crystal form of tofacitinib citrate was studied by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and powder X-ray diffraction (PXRD).
/
| 〈 |
|
〉 |